Pedro Vieira de Matos

Transition/GTMC

• Lead the development of Sanofi Pre-launch and Launch blueprint, namely the development of the new launch framework, new Launch Excellence Capabilities, and new cross functional launch playbooks.
• Lead the initial efforts towards the partnership with Mclaren on the Launch Simulator

SILC – From April 2025

• Work with SILC Head to support core team meetings preparation and delivery, SILC presentations and cross-department articulation (eg. Brand plan; GTMC; FTE Resource allocation, FLex, Plai). Partner with the core team members and business franchises to build SILC – Sanofi Integrated Launch Capabilities. Team Leadership. FLex recruitment and onboarding.
• Build SILC Foundations: Evolving the previous delivered work on playbooks and applying a standardized structure (ongoing). SILC KPIs – get to the first set of approved cross functional KPIs. Lead the efforts from SILC on KPIs definition and validation with the core team and support data integration. New pressure test on Tole ELC. IDCC Mapping
• Leapfrogging with SILC – Work together with Digital accelerator building SILC SUITE, namely defining the business requirements for SILC Navigator, SILC Mission control (KPIs monitor) and Governance. Support Launch Simulator team partnering with IQVIA to get relevant competitors data.
• Lead Amli Early adopters, partnering with Amli team on the deployment and pressure test of SILC Navigator and Mission Control; Amli global and US Launch plan; Launch deliverables mapping and Launch KPIs (ongoing Initiative).

• Evolve the Sanofi brand planning in Gen Med with strong focus in the early brand planning.
• Drive organizational transformation, paving the ground for the new LEX/MEX GTMC pillar and LEX/MEX COE leading the efforts on the organizational design, in full articulation with business stakeholders.
• Lead xGBU integration of global content transformation efforts (XCEED) through a standardized approach across SPC/GM/Vx, delivering the new Glocal XCEED Playbook.

• Member of Leadership Team of Western European Cluster (WEC): Top line of 2,5B$, 10 affiliates and 120 BE&S reports.
• Lead the Business excellence function, redesigning the operational model, identifying the right functional leaders at country level and building talent pipeline, ensuring the right capabilities in the different functional areas (Omnichannel; I&A and AI; LEX/MEX; Customer facing operations; Capability building). Creation and fostering of a strong WEC BE&S community, applying agile ways of working, finding solutions for common problems, innovate the go to market model and scale/SBP.
• Lead Launch Excellence efforts of Novartis key launch brands Kesimpta (MS); Leqvio (Cardio-Vascular); Kisqali (Oncology), driving pre-launch efforts and brand performance through revamped governance model and being an active contributor and challenger in the business discussions with the countries.
• Lead RE efforts in the implementation of new go-to-market models and local organizational design namely to support early pre-launch and local health ecosystem customization.
• Health care system shaping and patient journey optimization through innovative (digital) solutions to address major barriers in access to health, driving referrals, adherence to treatment, etc. Developed WEC as one of the critical Novartis incubators of innovation and platform for scaling across the organization. Innovative models using AI for patient identification, early adopter prediction and dynamic resource allocation.
• Lead customer engagement modernization and elevate customer experience through implementation of voice of the customer initiative, collecting consistently insights and implementing the adequate governance model so customer feedback is instilled in the critical business decisions.

• Member of leadership team. 10 Reports.
• Sponsor and lead the new organizational and operating model, piloting a new organization not based in the traditional franchise model but in account archetypes in a truly customer centric approach. Organizational design based on customer and market trends, health care system drivers, top line priorities and bottom-line efficiencies.
• Lead the Business excellence function and the core functional areas (Omnichannel; I&A and AI; LEX/MEX; Customer facing Operations; Capability building; CRM). Foster of a high performing team, delivering a new analytics platform and a new Integrated product strategy process. Implementation of new launch excellence model.

• MS portfolio lead with P&L responsibility, leading product launch and portfolio optimization. Lead of local strategy, marketing and sales teams and brand’s cross-functional activities (medical affairs, public affairs, market access, patient engagement and solutions, finance, communication, procurement).
• Pre-Launch and Launch of Mayzent- first product in the category (rSPMS), addressing a significant unmet need but requiring significant market shaping, innovative approaches to patient identification (genetic test), referrals, new customer engagement models and partnerships.
• Pre- launch Kesimpta - Unique selling preposition in a very competitive market with strong established players and after Ocrevus launch. Top 3 key asset for Novartis.
• Maximize Gilenya - #1 SPC asset (sales), overachieving peak sales and with double-digit growth under my tenure.
• Global Respiratory COPD lead/US/Top 5 EU Jul’17 –Jul’18. Basel
• Market shaping through redesigning COPD patient care journey, improving COPD screening, referrals and diagnosis, enlarging the COPD market. WW roll-out of Air Smart, first ever spirometer connected to mobile device allowing access to diagnosis in PC setting, something not possible before due to the lack of access to spirometry.

• Launch lead of Ultibro Breezhaler achieving #1 position (best launch WWV in COPD beating previous standard of care Spiriva). Strong excellence in execution in a very competitive market. Innovative partnership with the healthcare system with structural impact in the COPD landscape, creating a new program at the national level that allowed the inclusion of new COPD incentive in the health care system in the primary care setting which enabled earlier diagnose and therapy assessment.

• Business consultant to support organizational transformation of the commercial area of Imperio Assurance. Implementation of the new CRM. Report to the CEO.

• Stakeholder engagement, tenders and portfolio negotiation (Pharma and Oncology) in public and private hospital accounts.
• Healthcare shaping through strategic partnerships with key accounts in Diabetes, COPD (population health agreements), Oncology and Immunology. Establishment of excellence centers to ensure earlier diagnose, optimized treatment pathways, compliance, referrals, etc.
• “Winning for patients global award”

• Launch lead of Exjade NTDt indication, implementing the launch framework with excellency in execution (DNA talent development program)

• Lead strat plan, monthly business reviews, budgeting and resource allocation.
• Business excellence lead for oncology: brand planning, sales force effectiveness and market research and CI.
• National lead of CRM implementation for Pharma and Oncology.

• Lead of strategy function in a newly created organization delivering Brand building in the digital ecosystem: FMCG; Bank; telecommunications; energy and tourism.

• Business/technology consultant in 3 different industries:
• Medical Devices/Diagnostics - J&J/Ethicon (US and Global organization);
• Telecommunications
• Financial Services (Customer experienceMonitor ).

• Strategic Product Manager - Strategic marketing & Marketing operations
• Digital transformation in car insurance (Seguro Directo) and health insurance (Ageas/Médis).
• Set-up of a new insurance organization (Imperio comércio Indústria). Process reengineering and digital transformation “Millennium Excellence award”.